Introduction
Hematopoiesis occurs through a complex series of intricate, highly regulated intracellular steps, each of which ultimately contribute to the proper development of the body's myeloid, lymphoid and erythroid lineages. Unfortunately though, these processes sometimes become dysregulated due to overexpression of certain oncogenes, aberrant behavior of oncoproteins, and expression of chromosomal abnormalities, among others. Thus, the elaborate process of hematopoiesis can be changed from one that is necessary for life to another that is able to endanger it.
Our understanding of the cellular changes that occur in order for leukemogenesis to arise is essential for the development of successful therapies to treat these types of disorders. A prime example of how comprehending a cell's demise can lead to the development of an effective drug is the Bcr-Abl tyrosine kinase inhibitor STI571 (trademark name, Gleevec); STI571 functions by competitively inhibiting the binding site of ATP on the kinase thus preventing downstream activation and amplification of proliferative signals. In its first phase of clinical trials, STI571 proved to have hematologic responses in 53 out of 54 patients with chronic myelogenous leukemia (CML) within a 4-week period. 1 Furthermore, extensive testing is now underway to explore these promising results.
As alluded to above, the exploitation of knowledge gained from studying cell signaling pathways can be extremely attractive when considering chemotherapeutic options for treating a variety of neoplasia. The mitogen-activated protein kinases (MAPKs) are key regulators of embryogenesis, cell differentiation, cell proliferation, and even apoptosis; thus, the constituents of these pathways are also ideal candidates for novel anti-neoplastic chemotherapies. This review will focus on the MAP kinase cascades, the repertoire of proteins which comprise these pathways, and possible routes of chemotherapeutic intervention for leukemic disorders within these signaling cascades.
Overview of the MAP kinases
The serine/threonine MAP kinases are activated in response to upstream receptor tyrosine kinases and/or cytokine receptors that associate with heterotrimeric G proteins so as to trigger downstream pathways. The most extensively studied MAP kinase pathway is the Raf-MEK-ERK cascade. Just over a decade ago, the extracellular signal-regulated kinases (ERKs) were identified as a novel protein kinase family that exhibited proliferative effects when activated. [2] [3] [4] [5] Subsequent studies soon identified the upstream activators of ERK, the MEK (MAP/ERK kinase) family of kinases; the MEKs are dual-specificity kinases that can phosphorylate both serine/threonine and tyrosine residues on the MAP kinases. [6] [7] [8] A kinase responsible for activation of MEK is Raf and directly upstream of Raf is the GTPase, Ras. 9, 10 The Ras oncoprotein has been noted to be mutated in approximately 20% of all human malignancies. 11 Together, these proteins relay various stimuli to the cell nucleus, each of which ultimately contribute to cellular proliferation. 12 Another member of the MAP kinase family of proteins is the p38 kinase. The p38 group of MAPKs has been found to be involved in inflammation, cell growth, cell differentiation, cell cycle progression, and cell death. 13 p38 exists in four different isoforms: ␣, ␤, ␥ and ␦. [14] [15] [16] [17] Although each of these isoforms is moderately different in sequence(s) and structure(s), their activation loops each contain a TGY sequence motif. The p38 MAP kinases are selectively activated by two MEK isoforms, either MEK3 or MEK6. MEK6 appears to phosphorylate each of the p38 isoforms with little to no discrimination between each of them. However, MEK3 is only able to activate the p38␣ and p38␤ isoforms. 18 The third MAPK of interest is the c-JUN NH 2 -terminal protein kinase (JNK) which is also commonly referred to as the stress-activated protein kinase (SAPK). The JNK kinases are similar to the p38 family of kinases in that although many of the stimuli that activate these pathways are pro-apoptotic, the biological outcome of the aforementioned stimuli appears to be largely dependent on cell type. There are three JNK family members (JNK1, JNK2, JNK3) which are activated by two distinct MAPK kinases: MKK4/SEK1 and MKK7. [19] [20] [21] Each of the upstream mediators of JNK phosphorylation are activated in response to a variable number of stimuli including inflammatory cytokines (ie TNF and IL-1␤), UV light, reactive oxygen Overview of the MAPK cascades. The MAPK signal transduction pathways can be induced by either cytokines or stress. Activation of the different cascades can have diverse effects on cell growth, inflammatory responses, and/or apoptosis.
Leukemia increased tyrosine kinase activity on the intracellular portion of the receptor. Much of the tyrosine kinase activity is due to autophosphorylation that occurs within the two units of the receptor, where one acts as a kinase and the other as a substrate. 26 These phosphorylated residues then become docking sites for intracellular proteins that contain Src Homology-2 (SH-2) domains. Through this process, an intracellular conglomerate of proteins can initiate immediate signaling, in a variety of cascades, from the binding of one ligand to its receptor. [27] [28] [29] Dysregulated expression of either the ligand or the receptor can contribute to the development of neoplastic growth. Thus, targeting either the ligand or the receptor with chemotherapy is an ideal candidate for regulating uncontrolled signaling from within these complexes. This tactic would most likely be employed so as to neutralize the receptor with a synthesized ligand (or vice versa) by overexpression of such a molecule. This section contains a discussion of several growth factors, their receptors, and their roles in oncogenesis. Furthermore, possible sites for chemotherapeutic intervention will also be addressed.
Insulin-like growth factor-1 (IGF-1) receptor
IGF-1-R has been associated with a variety of types of carcinomas including breast cancer, 30 medullocarcinomas, 31 Ewing's sarcoma, 32 pancreatic tumors, 33 and a variety of leukemias, 34 among others. Most recently, researchers have been investigating the correlation between IGF-1-R/IGF-1-binding protein (IGF-1-BP) expression and survival in child patients with acute lymphoblastic leukemia (ALL). 35, 36 The mitogenic signal of the IGF-1 receptor/protein interaction is most often transduced via the PI3K pathway, 37 but sometimes signaling is relayed via either the MAPK pathway or by mitochondrial translocation of Raf-1. 38 Furthermore, it has been reported that two of these three pathways must be active for the mitogenic survival signal to proceed. 39 Because signaling through this receptor is able to lead to tumor development, it is an ideal candidate for chemotherapeutic intervention. A schematic representation of potential signal transduction pathways activated by IGF-1 is described in Figure 2 .
The IGF-1-R gene encodes for a polypeptide gene product that is subsequently proteolytically cleaved into ␣-and ␤-chains that ultimately comprise the receptor. Theoretically speaking, protease inhibitors should therefore be able to inhibit formation of the cleaved subunits of the IGF-1 receptor.
The IGF-1 receptor, specifically the ␤-subunit, has been found to be in an altered state in human leukemic cells where it exists as a larger (105 kDa), fetal version of the protein, thereby causing malignancy. 40 Accordingly, it has been a target of high priority for neutralization in leukemic disorders. As such, it has been shown, that when evaluating the potential role of IGF-1 as a growth-promoting factor in malignant lymphocyte development, that ALL cell lines will halt proliferation in response to the addition of anti-IGF-1R antibodies. 41 These results had been predicted from previous research which stated that both insulin and IGF-1 were able to stimulate growth of cultured, serum-starved human leukemia cells via their respective receptors. 42 Also, IGF-1R overexpression has been shown to be sufficient to abrogate the cytokine dependence of FDC-P1 hematopoietic precursor cells, an essential step in leukemogenesis. 43 Most recently, research has revealed that in patients with CML, treatment with interferon-␣ is able to increase expression of IGF-1R on lymphoid cells. Thus, overexpression of the IGF-1R may enable the immune system to mount a more efficient attack on the malignant cell clone by enhancing immunocompetent cell proliferation and action. 44 Perhaps the most intriguing aspect of the mitogenic signaling that occurs from the IGF-1 receptor is the level of crosstalk that is initiated through the PI3K pathway. As previously mentioned, the vast majority of signaling through IGF-1R occurs at the level of PI3K. PI3K is then able to activate Akt/PKB in an indirect manner so as to elicit anti-apoptotic effects. 45, 46 It is at this point that synergistic signaling has been reported. Recent evidence shows that when both Akt and Raf are active, the frequency of isolation of cytokine-independent hematopoietic cells increases over 100-fold. 47 A more indepth discussion about PI3K/MAPK interactions is discussed later in this review.
Platelet-derived growth factor (PDGF) receptor
PDGF family members are dimeric molecules with a conserved sequence of roughly 100 amino acid residues containing a motif of eight cysteine residues. There are three known existing isoforms, those being homo-and heterodimers of the A and B polypeptide chains. 48 More recently, though, additional PDGF isoforms have been discovered, known as PDGF-C and D, respectively. 49, 50 PDGF, like IGF-1, has been shown to activate both the Raf-MEK-ERK and PI3K pathways to induce cellular transform- ation. 51, 52 Furthermore, the development of chronic myelomonocytic leukemia and progression to AML is directly related to the constitutive activation of PDGF ␤ receptors as a result of an aberrant chromosomal translocation. 53, 54 The aforementioned activation of the PDGF receptor is a direct result of its translocation with the ets-like transcription factor, TEL. 53, 55 This association fuses the amino terminus of TEL, which contains the helix-loop-helix domain, to the transmembrane and cytoplasmic domains of the PDGF ␤ receptor causing constitutive PDGF-R activity. A similar oncogenic chromosomal translocation with TEL has been noted with the Janus associated kinase (JAK), whereby cytokine-independent cellular proliferation resulted. 56 Moreover, it has also been discovered that the PDGF-B (ligand) subunit is associated with the pathogenesis of marrow fibrosis associated with CML. 57 Lastly, the PDGF-A growth factor has been isolated from two pre-B ALL cell lines, implying a possible autocrine component to the transformation process. 58 Taken together, these data suggest that PDGF and its cognate receptor are ideal targets for drug therapies.
Researchers have developed PDGF antagonists at each level of PDGF-induced activation (ie ligand binding, receptor dimerization, and activation of the receptor kinase). An overview of these antagonists is depicted in Figure 3 . Neutralizing antibodies against both the PDGF protein isomers and the PDGF receptor proteins have been raised and tested in various animal systems. [59] [60] [61] [62] [63] [64] Nucleic acid ligands, known as aptamers, can also be used to neutralize PDGF signaling. Aptamers are generated by a process that selects for molecules with the highest binding capabilities over several rounds of binding to
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the protein of choice. After numerous selective rounds, a highaffinity molecule specific for the target is eventually isolated. This process is commercially known as systematic evolution of ligands by exponential enrichment (SELEX) and is currently under extensive investigation. Recently, a group from Gilead Sciences isolated an aptamer specific for PDGF that has an astonishingly low equilibrium dissociation constant of less than 3 × 10 −10
. 65 Scientists have also found that PDGF-A-mediated DNA synthesis can be halted by overexpressing a segment of the extracellular portion of the PDGF receptor. 66 These proteins have been shown to inhibit PDGF mainly by preventing autophosphorylation as described earlier. Furthermore, these compounds are able to block PDGF activity with IC 50 values ranging from 100 nM up to 1 M. [67] [68] [69] As denoted previously, receptor dimerization is a critical step in transducing extracellular stimuli to the cell. This stage of mitogenic signal transduction also provides a potential for chemotherapeutic intervention. To illustrate this point, the use of monoclonal antibodies against specified domains of the PDGF receptor have been shown to significantly reduce and sometimes abolish PDGF-mediated signaling at IC 50 values of under 1 nM. 64 Furthermore, it was observed that antibodies directed at specific regions of the PDGF-R could inhibit autophosphorylation without interfering with actual PDGF binding. 64, 70 Ultimately, it is the kinase activity of the PDGF receptor that transduces the extracellular signal to activate intracellular oncogenes. As such, several compounds have been developed that specifically target the PDGF-R kinase. These tyrosine kinase inhibitors are normally low molecular weight proteins that function to compete with ATP-binding at the kinase active site. Over the past decade, a number of compounds have been developed including AG1296, 71 78 each of which binds non-discriminately to the kinase(s) of the different PDGF receptor isoforms. Each of the aforementioned inhibitors has been applied to animal models with some success; but, by far, STI-571 has been pegged as the next miracle drug in leukemic therapies. 79, 80 Lastly, other similar compounds have been synthesized and used successfully in in vitro models, but have not yet been tested in animal models. 81, 82 
IL-3 and GM-CSF receptors
IL-3 and GM-CSF possess unique receptors, in that they lack intrinsic tyrosine kinase activity as compared to the PDGF-R and IGF-R. To compensate for this shortcoming, the ␤ c chain of the receptor is able to recruit specific kinases in order to transduce extracellularly derived signals. One of the prototypical kinases that serves this function is the JAK2 kinase. The ␤ c chain is also able to attract the adaptor molecule, Shc, which allows for the association of growth factor receptor-bound (Grb) protein and mammalian son of sevenless (SOS), each of which enables subsequent activation of the Ras oncoprotein. It is thought that an 85-kDa protein, identified as the p85 subunit of PI3K (described in more detail later) is also able to bind to the ␤ c chain, thus enabling activation of the PI3K signal transduction pathway. 83 These biochemical events each lead to DNA synthesis and prevention of apoptosis.
Hematopoietic cells can become transformed in response to mutation(s) occurring within the IL-3 gene which impart constitutive IL-3 expression. [84] [85] [86] [87] Furthermore, overexpression
Leukemia of the IL-3R ␣-subunit allows for hematopoietic cellular proliferation in suboptimal concentrations of the cytokine, IL-3.
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This observation has recently been supported by researchers who have found that the IL-3R ␣-subunit is a unique marker for detection of acute myelogenous leukemia (AML) cells, as it is overexpressed in primitive leukemia cells. 89 Conversely, constitutive expression of the ␤ c chain of IL-3R or GM-CSFR mutants imparts acute, chronic myeloproliferative disorder(s) in murine hematopoietic cells. [90] [91] [92] It is also interesting to note that a truncated isoform of the ␤ c chain of the GM-CSF, IL-3, and IL-5 receptors has been found overexpressed in patients with AML and ALL; this isoform appears to block signal transduction in an unexplained manner resulting in malignant transformation. 93 The development of monoclonal antibodies specific for distinct domains of the aforementioned receptors has shown promise over the past few years. A monoclonal antibody has been developed that is specific for a region of the IL-3R. 94 Shortly thereafter, monoclonal antibodies were generated to target the IL-3R, but these also bound the GM-CSF and IL-5 receptors due to their high degree of homology on their ␤ c chains. 95 The vast majority of the research done to antagonize the IL-3 and GM-CSF receptors over the past few years has been in the area of toxic fusion proteins. DT388-GM-CSF, a fusion protein derived from a truncated diphtheria toxin and GM-CSF, has been shown to cause death in AML cells expressing the GM-CSF receptor. 96 This effect was not evident in nontransformed hematopoietic progenitor cells, thus providing a rational chemotherapy for the treatment of AML. These experiments have been extended to an array of leukemic disorders, including juvenile and chronic myelomonocytic leukemias, each of which is susceptible to DT388-GM-CSF. 97, 98 Nearly identical studies have been performed using the same truncated diphtheria toxin attached to IL-3. These studies have also yielded positive results with respect to purging leukemic cells from bone marrow grafts. 99, 100 Recently, modified and chimeric cytokines have been developed to aid in the repopulation of hematopoietic cell compartments following myelosuppressive chemotherapy. Daniplestim is an engineered IL-3 receptor agonist created by truncations and amino acid substitutions to the native IL-3 protein. It can bind to the IL-3 receptor with significantly higher affinity than native IL-3.
101,102 Myelopoietin-1 belongs to a family of engineered chimeric molecules with dual agonistic capabilities for the IL-3 and G-CSF receptors. 101, 102 When fused together to produce a chimeric cytokine, these proteins have an enhanced ability to suppress apoptosis in hematopoietic cells. 101, 102 Furthermore, chimeras between G-CSF and FLT-3 ligand have also been developed and show potential for preventing apoptosis in certain cells, as well as dendritic cells. 103, 104 These types of studies should provide much needed insight into post-chemotherapeutic care in leukemia patients.
Target: Ras
The 21-kDa Ras gene product is a monomeric membranelocalized G-protein that initiates MAPK signal transduction. It is approximated that Ras is mutated in nearly 20% of all cancers. 11 Within hematopoietic cancers, it has been seen that Ras is mutated in approximately 20% to 60% of AMLs. [105] [106] [107] [108] Because Ras is widely mutated in a variety of human malignancies and is a molecular switch in a network of signaling 
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Leukemia pathways, it has become an important target for the development of anticancer drugs. Ras is a membrane-bound guanosine triphosphate (GTP)/guanosine diphosphate (GDP)-binding (G) protein that acts to relay signals from the lipid-rich cellular membrane to the nucleus. These signals lead to protein synthesis, regulation of cell survival, cellular proliferation, and differentiation. After binding of a ligand to its cognate receptor, dimerization of that receptor occurs, as described previously. Dimerization causes the intracellular tyrosine kinase(s) to become phosphorylated, which then becomes bound by the SH2 domains of the adaptor proteins, such as Grb2. 109 Not only does Grb2 possess an SH2 domain, but it also has an SH3 domain that binds to proline-rich motifs of other peptides (ie son of sevenless (SOS)). SOS is a guanine dissociation stimulator of Ras which binds to Ras after receptor activation. Ras' native conformation is then compromised and GDP is dissociated from Ras, allowing for the subsequent association of GTP. In the GTP-bound form, Ras is in its active state and able to recruit Raf to the cell membrane, thus enabling activation of Raf. [110] [111] [112] [113] However, there exist several GTPase-activating proteins (GAPs) that are able to stimulate the GTPase activity of Ras, which convert it back to its original inactive, GDPbound state. 114 There have been three main approaches taken to inhibit Ras-mediated signaling: (1) prevention of membrane localization of Ras; (2) inhibition of Ras protein expression via antisense nucleotides or RNAs; and (3) inhibition of kinases downstream of Ras (to be covered at each individual kinase level). Each of these approaches has been successful, to varying degrees, in blocking the proliferative effects of Ras activation.
In order for Ras to become active, it must undergo posttranslational modifications that add farnesyl or geranylgeranyl isoprenoid moieties to its carboxy-terminus. These modifications are generated by three different enzymes, namely farnesyltransferase (FT), geranyltransferase type I (GGTI), and GGTII. By blocking the enzymatic action of these enzymes, Ras is unable to localize to the cellular membrane where it mediates proliferative signaling (Figure 4) . Therefore, the development of FT inhibitors is a viable strategy used to inhibit the oncogenic effects of Ras. At the time of publication, there are currently four FTIs in clinical trials worldwide: R115777, SCH66336, L-778123 and BMS-214662. 115 R115777 has undergone phase I clinical trials and was found to significantly reduce Ras-mediated signaling. 116, 117 Similar results were observed for the compound SCH66336. 118 There are some data that argue that the effects of FTIs are not only due to the inhibition of Ras farnesylation, but also due to the inhibition of farnesylation of other proteins essential for cellular proliferation. RhoB is a 21-kDa G-protein that helps regulate receptor signaling and, in addition, is a target of FT inhibitors. Du and Prendergast 119 showed that in the presence of FTIs, RhoB became geranylgeranylated (RhoB-GG) in high quantities. At these concentrations, it was found that RhoB-GG became toxic to malignant cells, but not normal cells. A second hypothesis dealing with the mechanism of anti-tumor activity elicited by FTIs has also recently been developed. Jiang et al 120 have demonstrated that FT inhibitors are able to inhibit PI3K-mediated signaling and induce apoptosis in cancer cells that overexpress the AKT2 isoform. Supporting this hypothesis are data that indicate that FTIs are able to block a downstream kinase of PI3K, specifically p70 S6K . 121 Research has also been done to examine the effects of targeting specific RNA sequences to inhibit translation of the Ras RNA message into a functional protein. This antisense approach uses oligonucleotides, which are complementary to mRNA transcripts of the Ras oncogene. These oligonucleotides hybridize to the complementary mRNAs and inhibit their subsequent translation into protein(s). Malignant phenotypes have been observed to be suppressed in response to a retroviral vector-induced transduction of K-Ras antisense RNA of human cancer cells. 122, 123 A second, similar approach has also been used to inhibit abnormal Ras expression. This method employs the use of plasmid vectors encoding antisense RNAs that are able to inhibit tumorigenic growth. 124 
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Target: Raf
Raf-1 was the first identified downstream effector kinase of Ras and is currently the most characterized substrate of Ras. However, two other Raf isoforms are known to exist, those being A-Raf and B-Raf. This family of kinases has been suggested to have both overlapping and unique regulatory functions. [125] [126] [127] All three of the Raf isomers have been found to be expressed in hematopoietic cells of either lymphoid or myeloid lineages. 23, 128, 129 The level of Raf expression in transformed hematopoietic cells has been noted to be elevated. [130] [131] [132] [133] However, it is not known whether the heightened level of Raf expression actually caused the cells to become transformed because the cell lines of interest were established tumors. Conversely, it is known that several mechanisms exist to elicit dysregulated Raf expression. They include point mutations, deletions, gene rearrangements and gene amplifications. [134] [135] [136] [137] [138] Thus, the collective evidence suggests that Raf is a viable anticancer target for chemotherapeutic intervention.
Raf activation occurs on a dual level. In the first step, active GTP-bound Ras recruits Raf to the plasma membrane, which allows subsequent interaction(s) with additional activators that are not well-described. [139] [140] [141] Though this step is necessary for activation of Raf, it is not sufficient to cause Raf activation. Therefore, a secondary stage of activation occurs when Raf is phosphorylated on tyrosine and/or serine/threonine residue(s). This is normally accomplished on tyrosine residues by a member of the Src family of kinases and on serine/threonine residues by protein kinase C (PKC) isoforms. [142] [143] [144] It is worthwhile to note that the S43, S259 and S621 residues found on mutant, non-active Raf are still able to be phosphorylated, suggesting that these residues are not distinct autophosphorylation sites. 145 Lastly, dimerization of Raf is also known to induce Raf activity. Therefore, drugs which are able to prevent potential dimerization(s) may be effective anti-signaling compounds. 146 Recently, it was reported that Ras is able to induce the heterodimerization of the Raf-1 and B-Raf isoforms. 139 The role that Raf heterodimers play in signal transduction is largely unknown. As such, elucidation of the role that each of the Raf oncogenes plays in tumor development is imperative for the development of drugs that can effectively treat leukemic disorders. This is an increasingly crucial issue because the different Raf oncogenes have been shown to possess diverse signaling properties in various cell types. 147 For example, A-Raf may promote cellular proliferation, whereas a different isoform such as B-Raf induces apoptosis and arrests cell cycle progression. 23, 148 Rationale mandates, then, that inhibitors to each kinase must be developed in order to properly regulate these kinases, as they may have opposing roles in either preventing or stimulating cellular proliferation.
Geldanamycin has been the mainstay with respect to Raf inhibition over the previous decade. In effect, though, geldanamycin does not inhibit Raf activity, rather it destabilizes a protein-protein interaction between Raf and heat shock protein (hsp) 90.
149 By binding to hsp90, geldanamycin precludes binding between Raf and hsp90 which ultimately prevents proper Raf signaling functions. 150 However, since many proteins interact with hsp90, geldanamycin is not a specific Raf inhibitor. 151 More recently, a second type of compound has been shown to destabilize the Raf protein: KF25706 and KF58333 are oxime derivatives of radicol that have been shown to exhibit anti-tumor activities by acting in a manner similar to geldanamycin. 152, 153 The chemical structures of these and other kinase inhibitors are presented in Figure 5 .
Leukemia
Alternative strategies exist to inhibit Raf-mediated signaling. RNA aptamers have been developed that bind to the Ras-binding domain of the Raf-1 isoform. These RNA molecules bind with fairly high dissociation constants (300 nM) and may be able to inhibit Ras-Raf signaling in mammalian cells. 154 Another approach has been to synthesize proteins that are able to antagonize the binding between Ras and Raf. 155 An additional method devised to inhibit Raf signaling is the development of antisense oligodeoxynucleotides that are specific for each isomer of Raf. 156 Further research into these types of compounds has yielded marginal results, though.
It is of critical importance to mention that Ras also signals through parallel pathways in addition to the Raf-MEK-ERK pathway. As such, chemotherapeutic intervention at any point along the pathway may affect the signaling capacities of these alternative pathways. However, discussing the cellular ramifications of these types of interactions is outside the realm of this review.
Target: alternative Raf kinases
Raf is activated by more than just Ras; the kinase suppressor of Ras (KSR), PKC and the Src and JAK families of kinases have all been implicated in the Ras-independent activation of Raf. [158] [159] [160] [161] [162] [163] Each of these kinases activates Raf in a unique, deliberate manner. Targeting their inactivation, collectively or individually, would result in decreased levels of Raf activity and the subsequent abrogation of unharnessed proliferation.
JAK kinases
The Janus family of kinases (JAKs) is a receptor-associated group of kinases that become phosphorylated in response to ligand-receptor binding. After dimerization of the receptor occurs, the JAKs become phosphorylated on tyrosine residues, most likely a result of cross-phosphorylation. After they are activated, the JAKs then are able to phosphorylate other tyrosine residues on the receptor. The phosphorylated residues then attract a variety of signaling molecules that each contain an SH2 domain which enables them to dock to the phosphorylation site. The signal transducers and activators of transcription (STATs) are a family of transcription factors that fall into the aforementioned group of SH2-containing signaling molecules. 164 When a STAT molecule binds to a phosphorylated residue, it then becomes phosphorylated by a JAK due to their close proximity. Phosphorylation allows the STATs to dimerize and enter the nucleus to act as transcription factors for genes that lead to altered phenotypes. 165, 166 WHI-P131 is a compound that has been observed to target JAK3 activity. 167 JAK3 has been noted to have a role in lymphoid development and function and thus is a viable candidate for chemotherapeutic intervention. WHI-P131 was able to induce apoptosis in the NALM-6 and LC1;19 human leukemia cell lines, suggesting that this compound may be an attractive candidate for future pharmaceutical endeavors. 168 A tryphostin derivative that acts as a kinase inhibitor, AG-490, has also been used to inhibit JAK activity. It was first observed in 1996 that this novel compound had apoptoticinducing properties in ALL cells. 169 Since then, AG-490 has been widely noted to act by inhibiting STAT3 activation and inducing apoptosis in leukemic cells. 170, 171 As such, this compound may be ideal for pharmacologically induced inhibition 
Protein kinase C (PKC)
PKC has been shown to be a potent activator of Raf-1. 172 As a result, blocking PKC has become another approach to halt Raf-MEK-ERK signaling in leukemic disorders. Staurosporine is a non-specific protein kinase inhibitor that has been shown to halt cell cycle progression at concentrations ranging from 1 to 100 nM. 173 Staurosporine analogues exist, namely UCN-101, which have a higher affinity for PKC isoforms. 174, 175 Furthermore, UCN-101 elicits both cell cycle inhibitory and antiproliferative effects in several tumor cell lines. 176, 177 Another staurosporine derivative, CGP 41251, has been developed and has also shown promise as a potential anti-tumor agent.
178-180
Kinase suppressor of Ras (KSR)
The kinase suppressor of Ras (KSR, also known as CAPK) has recently been identified to be a possible scaffolding protein for the entire Raf-MEK-ERK transduction cascade. 181 It was originally reported that KSR was a positive effector of Ras signaling that appeared to act either upstream of Raf or in a parallel pathway, but the exact nature of these interactions was not known. 182 However, more recent studies have indicated that KSR may play an integral role in membrane-associated scaffolding of the MAPK proteins of the Raf-MEK-ERK pathway. It has been noted that the kinase domain (CA5) of KSR is able to mediate direct interactions between both MEK1/2 and KSR. 183 A similar type of binding interaction is seen with the ERK1/2 kinases; KSR binds to these proteins via a serine-threonine rich domain (CA4) located adjacent to the kinase domain. 184 Interestingly, the interaction with ERK is dependent on Ras activation, whereas the binding to MEK seems to be constitutive. 185, 186 Raf-1/KSR interactions appear to be both Ras-dependent and located at the cytoplasmic membrane. 187 These data, taken together, suggest a unique signaling mechanism where KSR is able to promote the assembly on a multiprotein complex that brings MEK into close proximity with both its upstream activator, Raf, and its downstream substrate, ERK. Although much of the research done on KSR is relatively novel, one might hypothesize that inhibition of one or more of these interactions may have anti-neoplastic ramifications.
Target: mitogen-activated protein kinase kinase-1/2 (MEK-1/2)
Targeting the molecule directly downstream of Raf is another possibility for the rational design of anticancer drugs. The MEKs belong to a multi-gene family that includes MEK-1 to MEK-5. Of these isoforms, MEKs-3, 4 and 5 are relatively less characterized than either MEK-1 or MEK-2. The dearth of research associated with the former proteins may be directly correlated to the lack of detectable kinase activity observed with the initial research that has been completed. 188, 189 Con-
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versely, much research has been done on the MEK-1 and MEK-2 isoforms, some of which has shown that they exhibit similar homologies to each other including a proline-rich region, which appears to be essential for signal transduction capabilities. 190 Furthermore, MEK-1 and MEK-2 (hereafter MEK), are phosphorylated on distinct serine residues, S218 and S222 by the upstream Raf molecules. 191, 192 Phosphorylation of MEK on both of these residues has been reported to increase its activity by more than 7000-fold. 193 Moreover, mammalian cells have been observed to be transformed as a result of constitutively activated MEK. 194 Increased MEK activity has also been seen in a variety of leukemias including AML and CML. 195, 196 Additionally, aberrant MEK-1 activity has also been shown to have anti-apoptotic effects in hematopoietic cells. [197] [198] [199] [200] In all, these data suggest that targeting MEK with specific inhibitors may be sufficient to abrogate aberrant MAPK cell signaling.
PD098059 is a commercially available MEK inhibitor that functions by binding to, and thus preventing activation of, the dephosphorylated form of MEK-1. 201, 202 Studies have shown that PD098059 is not only able to impair cellular proliferation, but is also able to impact other cellular events including angiogenesis, differentiation, and apoptosis. [203] [204] [205] [206] [207] A second MEK inhibitor, U0126, was identified using a cellbased screen seeking inhibitors of phorbol ester-stimulated AP-1 transactivation. 208 This inhibitor, like PD098059, does not compete with ATP suggesting that its mechanism of action is not by binding the ATP site of the enzyme. The basis for the interactions that occur between these molecules is unknown due to the fact that there is a lack of any known crystal structure for either MEK-1 or MEK-2. 193 Recently, it was reported that MEK inhibition via the use of a novel inhibitor, PD184352, is able to suppress growth of tumors in mice. 209 Accordingly, this compound is presently undergoing phase I clinical trials in cancer patients. 210 Interestingly, it has also been recently seen that the PKC inhibitor, UCN-01, when combined with PD184352 (or alternate MEK inhibitors, PD098059 and U0126) is able to cause mitochondrial dysfunction and subsequent induction of apoptosis. 211 Therefore, evidence suggests that targeting the MEK component of the Raf-MEK-ERK signal transduction cascade may be a viable option for chemotherapeutic intervention in leukemic disorders.
Target: extracellular signal-regulated kinase (ERK)
ERK-1 and ERK-2 are 43/44 and 41/42 kDa kinases that are directly downstream of the MEKs. Phosphorylation of the ERKs mainly occurs as a result of growth factor/cytokine stimulation, but has also been shown to be activated by hydrogen peroxide, UV light, and ionizing radiation. [212] [213] [214] [215] [216] ERK-1 and ERK-2 phosphorylation occurs on residues T183 and Y185 for maximal activity. 6, 7, 188 When activated, ERK-2 is able to dimerize with other ERK-2 proteins (regardless of their activation state) and induce nuclear translocation. 217, 218 Once inside the nucleus, ERK-2 is thought to phosphorylate and subsequently activate a variety of nuclear targets including topisomerase II-␣, a cell cycle progression mediator. 219, 220 The primary cytoplasmic target of the ERK kinases is p90 RSK , also known as the ribosomal protein S6 kinase, but a wide array of other targets are known to exist. [221] [222] [223] Despite the abundance of information that directly correlates Ras-Raf-MEK activation with leukemogenesis, ERK activation is not as readily implicated in the process. Some reports Leukemia directly blame constitutive ERK activation for the onset of AML and/or CML. 224, 225 Others have reported conflicting results, suggesting that CML cell growth and differentiation are independent of ERK activation. 226 Another group has recently shown that Ras-mediated ERK activation is absent in primary AMLs, indicating that ERK is not an essential mediator of the development of leukemia(s). 227 Crosstalk between parallel pathways and/or the use of a variety of cell lines may help to explain the apparent contradiction in these reports.
One approach taken to inhibit ERK phosphorylation is through the generation of a competitive inhibitor. A 15-amino acid peptide was synthesized resembling the ␣-C helix of ERK-1 and then kinetic analyses were performed to determine the efficacy of ERK inhibition mediated by this molecule. The authors found that this peptide was able to inhibit ERK from binding to MEK via a competitive inhibition mechanism. 228 More recently, it was reported that ERK activation is inhibited by parallel activation of the stress-activated p38 MAPK . Upon phosphorylation, p38
MAPK binds to ERK, sequestering it away from MEK-mediated activation, effectively inhibiting the Raf-MEK-ERK signaling pathway at the level of the ERK protein. The p90
RSK kinase is a serine-threonine kinase that contains two functional kinase domains: an amino terminal kinase that phosphorylates substrates of RSK and a carboxy terminal kinase that enables the activation of RSK by ERK. 230 Three isoforms of p90 RSK are known to exist including RSK-1, RSK-2 and RSK-3, each of which exhibit approximately 75-80% sequence homology to one another. [231] [232] [233] p90 RSK is fully activated after phosphorylation on three distinct residues which requires three concerted steps. First, ERK phosphorylates p90 RSK on S369, which triggers phosphorylation of S386 by the carboxy terminal kinase. Lastly, the amino terminal kinase is phosphorylated on S227 by 3-phosphoinositide-dependent protein kinase-1 (PDK-1), which enhances RSK activity 100-fold. 234 It was later found that the S386 residue is located in a hydrophobic motif that acts as a docking site and is essential for PDK-1-mediated phosphorylation of S227. 235 This is an apparent linker that bridges both the PI3K and Raf-MEK-ERK pathways, as PDK-1 also serves to phosphorylate and activate the downstream mediator of PI3K, Akt, on T308. This is an area of increasing interest and thus, this type of crosstalk research merits further, more detailed investigations.
The substrates of p90 RSK include an array of transcription factors including cAMP-response element-binding protein (CREB), estrogen receptor-␣ (ER-␣), I-B/NF-B, and c-Fos. [236] [237] [238] [239] [240] The roles that each of these transcription factors (and others) play in the onset of leukemogenesis and cell cycle progression will be briefly discussed in the following section.
Target: nuclear transcription factors
Aberrant gene expression and the consequential development of neoplasia can be targeted at the transcriptional level by examining the mechanisms by which these dysregulated genes become activated. Transcription factors (TFs) are the nuclear proteins that directly influence specific gene expression by stabilizing the interactions between the RNA polymerase and the DNA template. In the unphosphorylated state, most TFs neither promote nor antagonize transcription of their respective genes. However, upon phosphorylation,
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Leukemia some TFs translocate from the cytosol to the nucleus so as to activate transcription of their respective genes (Table 1) . Others, originating in the nucleus, merely localize to their respective sequence(s) on the DNA template in order to enhance transcriptional efficiency. Research to antagonize these types of interactions between TFs and DNA is underway and preliminary findings are revealing that targeting TFs may be a sensible approach for the development of anti-neoplastic drugs.
Cyclic AMP (cAMP)-response element binding protein (CREB)
Activation of p90 RSK can lead to phosphorylation of the CREB transcription factor on S133. 241, 269, 270 CREB, when phosphorylated on this residue, is bound by the CREB-binding protein (CBP) that enhances stabilization of the post-translationally altered CREB protein. 271, 272 Furthermore, this phosphorylation event is correlated with activation of immediate-early genes that can cause tumorgenesis, such as c-fos. 243 
Activator protein-1 family of transcription factors (AP-1)
The AP-1 family of transcription factors include c-Jun, c-Fos and activating transcription factor-2 (ATF-2).
273 These components are able to dimerize with each other via leucine zipper domains in order to activate transcription of specific genes. 274 c-Jun is phosphorylated on serines 63 and 73 by JNK and is phosphorylated on C-terminal inhibitory sites by ERK1/2. [275] [276] [277] [278] [279] Phosphorylation of the N-terminal amino acids (S63/S73) leads to enhanced c-Jun activity, which is coordinated with Ha-Ras-mediated oncogenic transformation. 280 The AP-1 transcription factors are defined targets of the MAPKs. For example, Jun:Fos and Jun:ATF dimers have been implicated in Ras-mediated oncogenesis. 281 Moreover, both c-Jun and Fos are necessary for cellular transformation induced by Ras. [282] [283] [284] Evidence exists suggesting that p90 Anti-apoptotic factor GM-CSF 266 Growth factor c-Myc 267 Transcription factor Cyclin D1 268 Cell cycle regulator and ERK are able to phosphorylate c-Fos on a defined region of its C-terminus, thereby enhancing the proliferation of fibroblastic cell lines. 285, 286 Also, activation of both the JNK and MAPK pathways are sufficient to raise the protein levels and/or activity of c-Jun and c-Fos. 287, 288 Lastly, both p38 MAPK and JNK activation are necessary to elicit transformation induced by c-Jun.
RSK
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Nuclear factor-B NF-B is the generic name for a broad array of heterodimeric transcription factors that are key modulators of a number of genes involved in cellular proliferation and apoptosis. 290 NF-B is found in the cytosol complexed with the inhibitory protein, I-B. A number of stimuli are able to induce phosphorylation of I-B, which allows for the dissociation of the complex, I-B degradation by the proteasome, and subsequent NF-B activation. Upon activation, NF-B is able to translocate to the nucleus to enhance transcription of a variety of genes. Over 150 potential target genes have been identified for NF-B, a large proportion of which are cytokines required for immune responses. 291 The MAPKs can activate NF-B through several different mechanisms. MEKK-1, a kinase of the JNK pathway, has been reported to phosphorylate I-B both in vitro and in vivo. 292 Raf-1 and p90
RSK have also been shown to be I-B kinases, thereby inducing NF-B activation. [293] [294] [295] [296] Furthermore, the constitutively active RelA/p65 subunit of the NF-B protein has been isolated from adenocarcinomas. This activated transcriptional activator was found to be phosphorylated by MAPKs of the Raf/MEK/ERK pathway. 297 
c-Myc
The c-Myc oncogene product is a transcription factor that is able to regulate gene expression in both normal and neoplastic cells.
298-300 c-Myc is known to heterodimerize with two proteins: Mad and Max. 301 These proteins, when complexed,
495
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have diverse cellular effects. Myc:Max heterodimers activate transcription, while Mad:Max complexes repress gene expression from the same promoter. 302, 303 Recently, another c-Myc binding protein was discovered that possessed tumorsuppressor characteristics. This peptide, MM-1, complexes with c-Myc's transactivation domain to suppress its regulatory capacities. 304, 305 Activated ERK dimers are c-Myc kinases that traverse the nuclear membrane to phosphorylate c-Myc on S62, thus stimulating activity of the transactivation domain. 306, 307 In contrast, another group reported that although MAPK phosphorylation of c-Myc occurs in vitro, the actual in vivo kinase(s) of c-Myc are still unknown. 308 Upstream of ERK, Ras is a mediator of c-Myc activation as it increases c-Myc transactivation over five-fold by interacting with the N-terminal region, perhaps by stabilizing the activated protein. 309, 310 In addition, a Raf-1 mutant which blocked Ras signaling caused by downregulation of c-Myc expression directly implicates the MAPK cascade in c-Myc regulation. 311 Interestingly, the stress-activated pathway, headed by the JNK kinase(s), has also been implicated in c-Myc activation, but in these cases, c-Myc activation can lead to apoptosis. 312 Together these data suggest that a degree of interplay can occur, perhaps mediated by distinct extracellular stimuli, that ultimately leads to either cell death or cellular proliferation by c-Myc.
Ets family of transcription factors
The Ets family of transcription factors has been implicated as one of the many downstream targets of the MAPK family (p38 MAPK , JNK and ERK), as well as the PI3K pathway. 313 This group of TFs is characteristically defined by a conserved winged helix-turn-helix DNA binding motif. 314 Current literature suggests that the Ets TFs are responsible for targeting over 200 different genes. 315 The targeted gene is a function of the protein heterodimers that occur as a result of activation. Two major groups of these TFs are currently defined: the Ets group which includes Ets1, Ets2 and Pointed, and also the TCF (ternary complex factors) family which include Elk1, Sap1a, Sap1b, Fli1 and Net. 316 The Ets subgroup has only one phosphorylation site located near the N-terminal domain, which is primarily activated by the Ras/Raf/MEK/ERK family. 317 The TCFs, though, are unique in that they have multiple serines and threonines within a transactivation domain that can be phosphorylated for activation. 318 This phosphorylation event is sufficient to allow for efficient binding to Ras-responsive elements (RREs) and/or serum response elements (SSEs) that exist in the promoters of multiple immediate-early genes, including c-fos, egr-1 and junB. 319 RREs require the binding of both an AP-1 dimer (previously discussed) and an Ets component. Therefore, gene expression controlled by these promoter sequences is immeasurably complex, considering that over 25 Ets members exist and that both the AP1 and Ets regulation are controlled coordinately by Ras. 316 The multifaceted and interwoven nature of the signaling pathways combined with the number of unique TF heterodimers that can occur help explain why these transcriptional activators and their mode(s) of action are not well understood.
Negative regulation of MAPKs: phosphatases
The premise of this review has been based on phosphoregulation of signaling cascades. The duration and degree of MAPK Leukemia activation is dependent on the delicate balance between the activating signal(s) and inactivation mechanism(s). As previously mentioned, ERK is fully activated by phosphorylation on both a tyrosine and a threonine residue. Removing a phosphate through the action of phosphatases from either of these residues results in decreased ERK activity. The predominant problem with phosphatase research to date has been the determination of their cellular localization. Consequently, there is little evidence that unequivocably implicates any particular phosphatase with any definite kinase. However, research into the actions and modalities of these negative regulators is underway and thus, is presented hereafter.
There is an array of dual-specificity phosphatases known as MAP kinase phosphatases (MKPs) that serve to dephosphorylate ERK. 320, 321 At the time of publication, there are seven known MKPs (MKPs1-7). MKP-1 is the original family member and was the first ERK phosphatase described. 322 MKP-2 (also known as TYP-1) was later isolated and also found to be an effective regulator of ERK activity. 323, 324 MKP-3 and MKP-4 were each soon described as ERK phosphatases. [325] [326] [327] The isolation of MKP-5 was the first phosphatase to be isolated that was not effective in inhibiting ERK activity. Rather, MKP-5 was observed to inactivate the stress-activated kinases, JNK and p38
MAPK . 328, 329 Most recently, MKP-7 has been isolated and found to be similar in function to that of MKP-5. 330 Lastly, MKP-6 is unique in that it functions as a novel negative-feedback regulator of CD28 costimulatory signaling that controls the activation of MAP kinases in peripheral blood T cells. 331 As previously alluded to, each of these phosphatases have distinct subcellular locales which imply the varying functions of these relatively homologous proteins. The utilization (ie overexpression) of one or several of the previously mentioned phosphatases in a pharmaco-preventative nature may help inhibit MAPK signaling and thus, halt uncontrolled cellular proliferation.
Of the above MKPs, two have been extensively reported to be effective in the dephosphorylation and subsequent inactivation of ERK molecules: MKP-1 and MKP-3. Activation of the Raf/MEK/ERK cascade has been reported to be of instrumental importance in the induction of MKP-1 expression to dephosphorylate ERK, which denotes the presence of an inhibitory feedback loop. 332 Further studies have endorsed this theory by showing that overexpression of MKP-1 is sufficient to increase both Raf and MEK kinase activities. 333 MKP-3 is another phosphatase that has been shown to dephosphorylate ERK. MKP-3 is activated merely by binding to ERK and functions primarily in the cytoplasm, whereas MKP-1 expression is reserved for nuclear activities. 334, 335 Protein phosphatases-1 and 2a (PP1 and PP2a) are a duo of dephosphorylating agents with highly conserved amino-acid sequences that remove phosphate groups from a wide array of phosphoproteins. 336, 337 It has been seen that these two phosphatases have an affinity for interaction with each of the components of the MAPK pathway (Raf, MEK and ERK). [335] [336] [337] [338] [339] [340] The role that these phosphatases play in regulating each of these proteins may be quite similar. One report showed that PP2a inactivation and MAPK activation are strongly correlated, indicating that PP2a plays a negative modulatory role in the regulation of MAP kinase activity. 341 Other reports, dealing with the Raf kinase, state that PP1 and PP2a dephosphorylate phospho-Raf, when it is bound to the 14-3-3 proteins, in order to allow for subsequent Ras-mediated activation of Raf. 342, 343 In each case, PP1 and PP2a activity permit the initiation of additional MAPK signaling. In addition, okadaic acid has been noted to be a potent inhibitor of both PP1 and
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PP2a phosphatase activities, albeit through a currently undescribed mechanism. 336, 344 The cellular phosphatases that act upon p90
RSK have not been identified as of yet.
Crosstalk: MAPK interactions with PI3K/Akt
As alluded to previously, the PI3K/Akt pathway is one that often transduces signals that are similar in nature to that of the Raf/MEK/ERK pathway. It has been shown that a certain degree of crosstalk exists between these pathways, which either enhance or sometimes negate oncogenic extracellular signals. By understanding the interactions that occur between the components of these pathways, we will be better advised in the development of treatment strategies that are able to more efficiently target leukemic cells within the body. Phosphatidylinositol 3-kinase (PI3K) is located in the cytoplasm in resting cells. It exists as a dimer of two subunits: a regulatory p85 subunit combined with a catalytic p110 component. 345, 346 Upon activation of a receptor tyrosine kinase and subsequent autophosphorylation, the SH-2 domain(s) of the p85 regulatory subunit bind to the receptor's phosphorylated Y residues.
83 PI3K then generates a series of phosphorylated lipids at the cytoplasmic membrane that act to recruit the phosphatidylinositol-dependent kinases (PDKs) and their downstream substrate Akt/PKB to the membrane. 347, 348 PDK1 serves to phosphorylate Akt on T308, whereas PDK2 phosphorylates S473 of Akt. [349] [350] [351] [352] Activated Akt is then able to phosphorylate a variety of downstream substrates each of which enable the cell to proliferate including the pro-apoptotic molecule BAD, caspase-9 (human cell lines), the forkhead family transcription factors, and I-K, a kinase that regulates the NF-B transcription factor. [352] [353] [354] [355] [356] [357] An overview of the potential interactions within this pathway are depicted in Figure 6 .
Abrogation of oncogenic signals from the PI3K pathway occurs via the tumor suppressor gene product, PTEN. 358 PTEN is a phosphatase that acts by removing a phosphate group from the 3 position of the inositol ring of the PIP 3,4,5 phospholipids located at the cellular membrane. [359] [360] [361] [362] In doing so, the
Figure 6
Roles of the PI3K/Akt pathway in growth and the prevention of apoptosis.
PDKs and Akt are not brought into close proximity to each other. Thus, activation of Akt is minimal, if at all. The theory that presence of a functional PTEN phosphatase is essential for the prevention of tumorigenesis is endorsed by data that showed that PTEN −/− mice either die during embryogenesis or spontaneously develop a variety of tumors later in life. 363, 364 Two pharmacological inhibitors of PI3K have been used extensively over the past decade. Wortmannin, originally known as an inhibitor of respiratory burst activities, has been shown to be a potent inhibitor of PI3K-mediated signaling. 365, 366 LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] is another inhibitor of PI3K that has been used with high degrees of efficacy at low IC 50s (1.4 M).
367
The two aforementioned inhibitors have been useful in blocking PI3K signaling, but have no capacity to directly inhibit Akt activity. More recently though, CalBioChem (San Diego, CA, USA) has developed a highly potent, quasi-specific inhibitor of Akt known as IL-6-hydroxymethyl-chiro-inositol-2(R)-2-Omethyl-3-O-octadecylcarbonate. This compound has been seen to selectively inhibit Akt activity with an IC 50 of approximately 5.0 M, while only faintly affecting PI3K activity. 368 Further studies using this inhibitor should provide valuable insight into Akt-mediated signaling, especially that independent of PI3K.
Crosstalk between the PI3K and Raf/MEK/ERK pathways has been reported on multiple levels, with some research stating that PI3K activity is essential for induction of Raf/MEK/ERK activity. [369] [370] [371] Additional studies suggest that the PI3K pathway enhances and/or synergizes with Raf/MEK/ERK signaling to provide a more robust signal through the lower components of the MAPK cascade (ie ERK). 47, [371] [372] [373] However, there is conflicting evidence that states that Akt is able to phosphorylate Raf, thereby efficiently abrogating Raf activity on downstream substrates. [374] [375] [376] Furthermore, some data suggest that this effect may be dependent upon the differentiation state of the cell, which may account for the apparent discrepancies in the current literature. 377 Regardless of cell type, differentiation state, or assay conditions, it is quite apparent that there is a varying degree of crosstalk that occurs between these pathways. Examining the level, nature and circumstances by which these interactions occur will be instrumental in the development of new agents designed to battle leukemia.
Conclusions
The Raf/MEK/ERK signal transduction cascade is responsible for many of the phenotypes observed in a wide array of oncogenic disorders, including leukemia. Drug intervention and/or the use of pharmacological inhibitors will be practical at each level of this cascade, from the cell receptor at the plasma membrane to the transcription factors at the nucleus. This review would be remiss if it did not address the importance of acknowledging the complexities of the signal transduction and apoptotic pathways discussed (a more detailed, but not all-encompassing schematic is shown in Figure 7 ). All conclusions drawn are not necessarily true for all cell types and the degree of crosstalk that occurs between parallel pathways remains largely unknown. 378, 379 Furthermore, blocking the activity of a protein far upstream of others (ie Ras) may have other injurious effects that were not intended, as inhibiting its activity may also suppress other vital functions. Conversely, by inhibiting the activity of a downstream component of the MAPK pathway (ie p90 RSK ), one may overlook alternative mechanisms by which the cell is able to bypass 
SPOTLIGHT
Figure 7
Sites of interaction of various inhibitors of cytokine and stress-mediated signal transduction.
that signaling component. For that reason, a multi-tiered approach targeting the inhibition of uncontrolled cell signaling may be merited. The hallmark of every neoplasia is uncontrolled cellular proliferation. This aberrant behavior relies on a series of overexpressed oncogenes and on the accumulation of tumor-suppressor gene mutations. The combinatorial effects of these genotypes are detrimental not only to the cell, but also to the entire body. If the cellular processes by which these anomalies occur are better understood, then scientists can begin to exploit that knowledge so as to develop more effective, non-invasive chemotherapeutic treatments.
